European Patent Organisation

ESAs’ Board of Appeal dismisses case against the EBA on alleged non-application of Union law as manifestly inadmissible

Friday, January 15, 2021 - 4:06pm

In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.

Key Points: 
  • In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.
  • In addition, the Board of Appeal notes that the Appellant, at the time of filing this new appeal, was fully aware of the reasons of inadmissibility of the appeal filed against ESMA and EIOPA.
  • The Board of Appeal, therefore, considers the appeal as manifestly inadmissible and does not allow for any further consideration.
  • The appeal against EBAs communication of 21 December 2020 was filed with the Board of Appeal on 22 December 2020.

ESAs’ Board of Appeal dismisses case against the EBA on alleged non-application of Union law as manifestly inadmissible

Friday, January 15, 2021 - 4:03pm

In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.

Key Points: 
  • In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.
  • In addition, the Board of Appeal notes that the Appellant, at the time of filing this new appeal, was fully aware of the reasons of inadmissibility of the appeal filed against ESMA and EIOPA.
  • The Board of Appeal, therefore, considers the appeal as manifestly inadmissible and does not allow for any further consideration.
  • The appeal against EBAs communication of 21 December 2020 was filed with the Board of Appeal on 22 December 2020.

ESAs’ Board of Appeal dismisses case against the EBA on alleged non-application of Union law as manifestly inadmissible

Friday, January 15, 2021 - 1:10pm

In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.

Key Points: 
  • In its decision, the Board of Appeal dismisses the Appellants claim as manifestly inadmissible as the facts described do not seem to involve a subject-matter within the remit of the EBA nor of the Board of Appeal.
  • In addition, the Board of Appeal notes that the Appellant, at the time of filing this new appeal, was fully aware of the reasons of inadmissibility of the appeal filed against ESMA and EIOPA.
  • The Board of Appeal, therefore, considers the appeal as manifestly inadmissible and does not allow for any further consideration.
  • The appeal against EBAs communication of 21 December 2020 was filed with the Board of Appeal on 22 December 2020.

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:41am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:40am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions

Tuesday, January 12, 2021 - 9:30pm

The new hearing date is set for September 6, 2021.

Key Points: 
  • The new hearing date is set for September 6, 2021.
  • On January 29, 2018, the Opposition Division of the EPO concluded the oral proceedings concerning the 355 Patent (the Opposition Proceeding).
  • Management expects the TBA to issue a ruling on the same day as the hearing, with a fully reasoned decision approximately two months following the hearing.
  • The denial of a request to rehear would end the Opposition Proceeding in favor of the opponents.

OncoZenge announces issue of European Patent related to BupiZenge®

Thursday, January 7, 2021 - 7:08am

STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge, currently in development for treatment of pain due to oral mucositis.

Key Points: 
  • STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge, currently in development for treatment of pain due to oral mucositis.
  • The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity.
  • It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients.
  • "The patent significantly strengthens the intellectual property for BupiZengein Europe", Pirkko Tamsen, CEO of OncoZenge comments.

OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology

Thursday, December 10, 2020 - 2:00pm

PENNINGTON, N.J. and SAN DIEGO, Dec. 10, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that the European Patent Office has issued notices of intention to grant for two patent applications.

Key Points: 
  • PENNINGTON, N.J. and SAN DIEGO, Dec. 10, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that the European Patent Office has issued notices of intention to grant for two patent applications.
  • The applications are directed to the use of OncoSec's interleukin-12 (IL-12)-based immunotherapy platform, including its lead product candidate TAVO (tavokinogene telseplasmid)delivered with the Company's proprietary intratumoral gene electrotransfersystem for the treatment of cancer.
  • Once granted, these two patents extend key patent coverage until March 24, 2036 and March 2, 2027 respectively.
  • "Pursuing these patents is important to strengthen the intellectual property protections around TAVO and our electroporation gene delivery system," said Daniel O'Connor, Chief Executive Officer of OncoSec.

U.S. is the World Leader in Patenting Fourth Industrial Revolution (4IR) Technologies

Thursday, December 10, 2020 - 1:00pm

MUNICH, Dec. 10, 2020 /PRNewswire-PRWeb/ --A study published today by the European Patent Office (EPO) shows that innovation in fourth industrial revolution (4IR) technologies has accelerated significantly worldwide.

Key Points: 
  • MUNICH, Dec. 10, 2020 /PRNewswire-PRWeb/ --A study published today by the European Patent Office (EPO) shows that innovation in fourth industrial revolution (4IR) technologies has accelerated significantly worldwide.
  • The study, entitled "Patents and the Fourth Industrial Revolution the global technology trends enabling the data-driven economy", looks at all international patent families (IPFs) related to 4IR worldwide between 2000 and 2018.
  • The study finds that nearly 40,000 new IPFs were filed for these technologies in 2018 alone.
  • This means they accounted for more than 10% of all patenting activity worldwide that year.

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Tuesday, December 1, 2020 - 2:00pm

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO).

Key Points: 
  • Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO).
  • European Patent Number 3209382, Combination Immunotherapy Approach for Treatment of Cancer, secures Calidis proprietary technology platform, Supernova 1 (SNV1), composed of the oncolytic agent, CAL1 vaccinia virus, loaded into allogeneic, adipose-derived mesenchymal stem cells (AD-MSC).
  • Were very excited to be granted this European Patent to protect our innovative immunotherapy product and combination approach abroad, said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics.
  • As of the EP Grant Date, November 25, 2020, the European Patent covers Calidis combination immunotherapy approach and SNV1 product in 37 contracting European countries.